Dihexa
Hexapeptide analog of angiotensin IV (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) developed for cognitive enhancement. Remarkably long circulating half-life of ~12.7 days (IV) due to serum stability. Crosses the blood-brain barrier. Activates hepatocyte growth factor (HGF)/MET signaling, promoting synaptogenesis. 10 million-fold more potent than BDNF in promoting neurite outgrowth in vitro.
Projected serum levels — 10 mg, once daily
Maintenance schedule: 10 mg once daily (oral).
Loading schedule: 30 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.
Modeled steady state after ~31 days: peak ≈ 80.4 mg, trough ≈ 80.1 mg body load. Population-based estimate over 97 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Peptide
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 13 days
- Common dose
- 10 mg
- Suggested maximum
- 20 mg/day
- Reference dose range
- 5–20 mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents
Foundational study characterizing dihexa as a BBB-permeable, serum-stable AngIV analog with half-life of 12.68 days (IV) that reversed scopolamine-induced cognitive deficits at picomolar concentrations.
-
AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway
Demonstrated dihexa rescued spatial learning and memory in APP/PS1 Alzheimer model mice via HGF/MET-PI3K/AKT signaling, reducing amyloid plaque burden and neuroinflammation.
2 published studies referenced in the app, each with a plain-language summary.